Kensey Nash Corp.
735 Pennsylvania Drive
Exton,
PA 19341
United States - Map
Phone: 484-713-2100
Fax: 484-713-2900
Web Site: http://www.kenseynash.com
| Kensey Nash Corporation, a medical device company, develops products and technologies in the fields of resorbable biomaterials and endovascular devices used in various medical procedures. The company develops, manufactures, and processes resorbable biomaterials products incorporating its proprietary collagen and synthetic polymer technology. It offers Angio-Seal components; orthopaedic products for various applications of biomaterials, which include soft tissue and bone fixation, and bone void fillers and scaffolds; and biomaterials-based products, including resorbable breast biopsy markers, dental barrier membranes, and wound care products designed for other market applications. The company sells its products to multiple medical markets, primarily in the cardiology, orthopaedic, sports medicine, spine, endovascular, and general surgery. The company distributes its endovascular products through direct sales force primarily in the United States and Germany, as well as through distributors in Europe, Russia, and India. It has strategic agreement with Synthes, Inc., under which the company would develop and manufacture porcine dermis-based Medeor matrix ECM products. The company was incorporated in 1984 and is headquartered in Exton, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Joseph W. Kaufmann , 57
Chief Exec. Officer, Pres, Sec. |
$
631.00K |
$
2.31M | Mr. Michael Celano C.P.A., 50
Chief Financial Officer |
$
117.00K |
$
0 | Mr. Douglas G. Evans P.E., 45
Chief Operating Officer, Assistant Sec. |
$
563.00K |
$
0 | Dr. Russell T. Kronengold Ph.D, 39
VP of Biomaterials Research |
$
232.00K |
$
91.00K | Mr. Todd M. DeWitt Ph.D, 55
VP of Biomaterials |
$
227.00K |
$
106.00K |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
0.57 (2.39%) 
Profile
